Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | CDK7 | P50613 | 3/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28775301 | 0.72 | NUDT1 (0.44) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL976118 | 0.70 | METAP2 (0.48) | MAPK1CDK5GSK3BGSK3A | |
| SCHEMBL23001498 | 0.67 | XDH (0.39) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL12791460 | 0.67 | MAPK1 (0.47) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL38654532 | 0.67 | MAPK1 (0.47) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL29255586 | 0.65 | PDE5A (0.31) | — | |
| SCHEMBL31634337 | 0.65 | MAPK1 (0.38) | MAPK1DYRK1A | |
| SCHEMBL15915542 | 0.64 | RET (0.52) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL30328922 | 0.64 | RET (0.52) | MAPK1ABL1RETKDRCDK7 | |
| SCHEMBL22958307 | 0.63 | ALDH1A1 (0.50) | MAPK1ABL1RETKDRCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | CYTOKINETICS, INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| US-8716291-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | disclosed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | MAPK1 2684/4885ABL1 2463/4885RET 1175/4885 |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, TNNC1 | MAPK1 2175/4885ABL1 342/4885RET 1494/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | MAPK1 2684/4885ABL1 2463/4885RET 1175/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | MAPK1 2382/4885ABL1 160/4885RET 3572/4885 |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | TNNI3, TNNT2, TNNC1 | MAPK1 2494/4885ABL1 2470/4885RET 3808/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | MAPK1 2684/4885ABL1 2463/4885RET 1175/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | MAPK1 2175/4885ABL1 342/4885RET 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.